Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition - Schedule of Total Consideration, Assets and the Liabilities (Details)

v3.24.3
Asset Acquisition - Schedule of Total Consideration, Assets and the Liabilities (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended
Aug. 13, 2024
Mar. 28, 2024
Mar. 27, 2024
Apr. 30, 2024
Sep. 30, 2024
Common stock          
Asset Acquisition, Contingent Consideration [Line Items]          
Conversion of stock, issuance(in shares)     6,585,314    
Almata Transaction And March 2024 Financing          
Asset Acquisition, Contingent Consideration [Line Items]          
Shares issuable in common stock (in shares) 349        
Almata Transaction And March 2024 Financing | Common stock          
Asset Acquisition, Contingent Consideration [Line Items]          
Conversion of stock, issuance(in shares) 8,648,244        
Series C Preferred Stock | Almata Transaction And March 2024 Financing          
Asset Acquisition, Contingent Consideration [Line Items]          
Shares issuable in common stock (in shares)     2,412    
Shares converted (in shares)     2,063   8,648
AlmataBio Transaction          
Asset Acquisition, Contingent Consideration [Line Items]          
Stock consideration         $ 12,272
Milestone payment due upon close of private placement investment   $ 7,500   $ 7,500 7,500
Milestone payment due upon first patient dosed in a Phase 2 trial         5,000
Transaction costs         2,402
Total GAAP Purchase Price at Close         27,174
Acquired IPR&D         27,641
Cash         356
Accrued expenses and other current liabilities         (823)
Total net assets acquired and liabilities assumed         $ 27,174
Common stock shares issued (in shares)     171,605    
Shares issuable in common stock (in shares)     2,412    
Convertible preferred stock, shares issued upon conversion (in shares)     2,412,000    
Closing stock price (in dollars per share)     $ 4.75    
AlmataBio Transaction | Common stock          
Asset Acquisition, Contingent Consideration [Line Items]          
Conversion of stock, issuance(in shares)     2,062,930